RxDoctor Payments Data

Nanette Wenger, MD

Cardiovascular Disease · Atlanta, GANPI 1033214622

Payments from drug & device makers

$27,701in general payments, 2019–2025

Across 38 payments — averaging $728.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Amarin Pharma, Inc.$6K
  • Roche Diagnostics Corporation$6K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Philips North America LLC$150
  • Merck$138
  • plus $190 from 3 others

What the payments were for

  • Consulting fees$9,65835%
  • Speaking & faculty fees$12,50045%
  • Travel & lodging$4,53616%
  • Food & beverage$1,0064%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,701 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$9,806
Medicare patients
261
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol124$180,545
EntrestoSacubitril/Valsartan49$66,716
EliquisApixaban51$59,396
OzempicSemaglutide37$55,795
JardianceEmpagliflozin32$48,944
XareltoRivaroxaban26$31,965
Metoprolol Succinate150$2,238
Atorvastatin Calcium210$1,868
Torsemide37$979
Rosuvastatin Calcium89$937
Carvedilol135$906
Ezetimibe65$863
Nifedipine ErNifedipine28$822
Losartan Potassium93$710
Amlodipine Besylate133$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$100$66,71649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →